Skip to main content

17 Result(s)

within Medicine & Public Health Remove this filter Hematology Remove this filter J Reiffers Remove this filter Chapter Remove this filter

and

  1. No Access

    Chapter and Conference Paper

    Treatment of Relapsed or Refractory Acute Leukemia: Comparison of Two Different Regimens

    The treatment of relapsed or refractory acute leukemia (AL) remains problematic. The use of high-dose cytosine arabinoside (HD Ara-C) appears promising [1] and its association with M-amsacrine (M-AMSA) has ach...

    G. Marit, P. Cony, F. Duclos, M. Puntous, A. Broustet, J. Reiffers in Acute Leukemias II (1990)

  2. No Access

    Chapter and Conference Paper

    Incomplete Stroma Formation by Bone Marrow from Chronic Myeloid Leukemia Patients Treated with Interferon

    Chronic myeloid leukemia (CML) results from the neoplastic transformation of a pluripotent stem cell. The disease is characterized by a significantly increased number of granulo-monocytic progenitors in both t...

    A. Rice, J. Reiffers, Ph. Bernard, C. Foures… in Cytokines in Hemopoiesis, Oncology, and AI… (1990)

  3. No Access

    Chapter

    Purged Autologous Bone Marrow: Better or Worse than Circulating Stem Cells?

    Autologous bone marrow tranplantation (ABMT) has been extensively used as treatment for hematological malignancies over the last decade [1]. The main cause of failure after ABMT is relapse or recurrence of the...

    J. Reiffers in Advances in haemapheresis (1991)

  4. No Access

    Chapter and Conference Paper

    Possible Effect of Autologous Blood Stem Cell Transplantation on Outcome of Acute Myeloid Leukemia in First Relapse

    Despite recent progress in the treatment of acute myelogenous leukemia (AML), most patients who achieve complete remission (CR) relapse within 2 years following induction chemotherapy. In some of these latter ...

    J. Reiffers, G. Marit, P. Cony-Makhoul, C. Faberes, P. Fernandez… in Acute Leukemias (1992)

  5. No Access

    Chapter and Conference Paper

    Prospective Study Comparing Idarubicin and Daunorubicin in Elderly Patients with Acute Myeloid Leukemia

    There is general agreement about the use of a combination of cytosine arabinoside (Ara-C) and anthracycline as induction chemotherapy for patients with acute myeloid leukemia (AML). Cytosine arabinoside is usu...

    J. Reiffers, F. Rigal-Huguet, A. M. Stoppa, M. Michallet, G. Marit… in Acute Leukemias (1992)

  6. No Access

    Chapter and Conference Paper

    Use of Recombinant Interleukin-2 (RU 49637) After Autologous Bone Marrow Transplantation in Patients with Hematological Disease: Phase I–II Study

    Allogeneic bone marrow transplantation (BMT) is currently an established therapy for hematological malignancies. Twenty years of experience has demonstrated that curability comes from both tumor ablation due t...

    D. Blaise, D. Olive, M. Brandely… in Cytokines in Hemopoiesis, Oncology, and AI… (1992)

  7. No Access

    Chapter and Conference Paper

    Treatment of Relapsed Acute Myeloid Leukemia with Granulocyte-Macrophage Colony-Stimulating Factor and Intensive Chemotherapy

    The treatment of relapsed acute myeloid leukemia (AM L) often involves the use of high-dose cytosine arabinoside (ara-C) [10]. The combination of ara-C and amsacrine gives good results [3], permitting a comple...

    M. Puntous, F. Lacombe, G. Marit, P. Dumain… in Cytokines in Hemopoiesis, Oncology, and AI… (1992)

  8. No Access

    Chapter and Conference Paper

    Toxicity Profile of Idarubicin: Experiences with Oral and Intravenous Idarubicin in the Treatment of Leukemia

    Idarubicin (IDR) is a new potent antileukemic agent and the only anthracycline derivative in current use that can be administered orally. We review here the French experience with oral and IV IDR.

    J. L. Harousseau, B. Pignon, J. Reiffers, F. Rigal-Huguet, J. Y. Cahn… in Acute Leukemias (1992)

  9. No Access

    Chapter and Conference Paper

    The In Vitro Effect of Interferon-γ on Chronic Myeloid Leukemia Cells

    Chronic myeloid leukemia (CM L) results from the neoplastic transformation of a pluripotent hematopoietic stem cell [1]. At present the only curative treatment for this disease is an allogeneic bone marrow tra...

    A. Rice, M. Becker, G. Marit, P. Bernard… in Cytokines in Hemopoiesis, Oncology, and AI… (1992)

  10. No Access

    Chapter and Conference Paper

    Bone Marrow Transplantation for Chronic Myeloid Leukemia in France. Results of the French Cooperative Group

    Transplants were performed in 281 patients (pts) with chronic myeloid leukemia (CML) in France between 1979 and 1986. The actuarial survival after 5 years is 55% for the patients receiving grafts in first chro...

    A. Devergie, J. Reiffers, J. P. Vernant, P. Hérvé, D. Guyotat, D. Maraninchi… in Leukemias (1993)

  11. No Access

    Chapter

    The Use of Long-Term Culture Techniques to Study Peripheral Blood Stem Cells Before and After Autologous Transplantation

    Autologous blood stem cells collected during the recovery phase after intensive chemotherapy are rich in progenitor cells, and, when infused into patients who have received myeloablative therapy, lead to rapid...

    A. Rice, C. Foures, P. Bernard, G. Marit… in Peripheral Blood Stem Cell Autografts (1993)

  12. No Access

    Chapter and Conference Paper

    Recombinant Human Erythropoietin After Bone Marrow Transplantation — A Placebo Controlled Trial

    Several historically controlled studies [1,3,5] and one small open prospective randomized trial [4] showed an acceleration of erythropoietic recon-stitution after allogeneic bone marrow transplantation (BMT). ...

    H. Link, M. A. Boogaerts, A. Fauser, R. Or, J. Reiffers, N. C. Gorin… in Acute Leukemias V (1996)

  13. No Access

    Chapter and Conference Paper

    IL2 in Acute Leukemia

    Immunotherapy is a logical approach for the strategy of a currative treatment for acute leukemia since allogeneic bone marrow transplantation had demonstrated the benefit of graft versus host disease (GVHD) to...

    D. Blaise, A. M. Stoppa, M. Attal, J. Reiffers, J. Fleury… in Acute Leukemias V (1996)

  14. No Access

    Chapter and Conference Paper

    Peripheral Blood Stem Cell Transplantation in Acute Myeloid Leukemia

    Autologous peripheral blood stem cell (PBSC) transplantation was first successfully performed in patients with acute myelogenous leukemia (AML) during the mid 1980s. Since these reports [1-3], the number of pa...

    J. Reiffers, J.-M. Boiron, P. Cony-Makhoul, G. Marit, F.-X. Mahon… in Acute Leukemias VI (1997)

  15. No Access

    Chapter and Conference Paper

    Allogeneic and Autologous Bone Marrow Transplantation and Chemotherapy in First Remission of Adult Acute Lymphoblastic Leukemia: Results of the LALA 87 Trial of the French Group

    In a prospective study of 317 acute lymphoblastic leukemia (ALL) patients aged 15–40 years and in complete remission, 257 had a potential donor and one HLA ty** analysis; A total of 116 patients were allocat...

    D. Fière, J. P. Vernant, J. Reiffers, J. M. Miclea, F. Witz… in Acute Leukemias VI (1997)

  16. No Access

    Chapter and Conference Paper

    Early Allogeneic Transplantation Favorably Influences the Outcome of Adult Patients Suffering from Acute Myeloid Leukemia

    Allogeneic BMT for patients with acute myeloid leukemia (AML) is presently a reference therapy. The indications for this therapy may likely rely upon prognostic factors, and their importance are constantly inv...

    E. Jourdan, D. Maraninchi, J. Reiffers, E. Gluckman, B. Rio… in Acute Leukemias VII (1998)

  17. No Access

    Chapter and Conference Paper

    Blood Stem Cell Transplantation in Acute Myeloid Leukemia

    Autologous blood cell transplantation (BCT) is an alternative to autologous bone marrow transplantation (BMT) for patients with acute myeloid leukemia (AML) in first remission. Its main advantage is that it is...

    J. Reiffers in Acute Leukemias VII (1998)